ES2191320T3 - Derivados de piperazina y su uso como agentes anti-inflamatorios. - Google Patents
Derivados de piperazina y su uso como agentes anti-inflamatorios.Info
- Publication number
- ES2191320T3 ES2191320T3 ES98937467T ES98937467T ES2191320T3 ES 2191320 T3 ES2191320 T3 ES 2191320T3 ES 98937467 T ES98937467 T ES 98937467T ES 98937467 T ES98937467 T ES 98937467T ES 2191320 T3 ES2191320 T3 ES 2191320T3
- Authority
- ES
- Spain
- Prior art keywords
- inflammatory agents
- derivatives
- piperazine
- compounds
- relates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229940121363 anti-inflammatory agent Drugs 0.000 title abstract 2
- 239000002260 anti-inflammatory agent Substances 0.000 title abstract 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical class C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- -1 acyl piperazine derivatives Chemical class 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87359997A | 1997-06-12 | 1997-06-12 | |
US09/094,397 US6207665B1 (en) | 1997-06-12 | 1998-06-09 | Piperazine derivatives and their use as anti-inflammatory agents |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2191320T3 true ES2191320T3 (es) | 2003-09-01 |
Family
ID=26788818
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES98937467T Expired - Lifetime ES2191320T3 (es) | 1997-06-12 | 1998-06-11 | Derivados de piperazina y su uso como agentes anti-inflamatorios. |
ES02090193T Expired - Lifetime ES2242824T3 (es) | 1997-06-12 | 1998-06-11 | Derivados de piperazina y su uso como agentes anti-inflamatorios. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES02090193T Expired - Lifetime ES2242824T3 (es) | 1997-06-12 | 1998-06-11 | Derivados de piperazina y su uso como agentes anti-inflamatorios. |
Country Status (22)
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207665B1 (en) * | 1997-06-12 | 2001-03-27 | Schering Aktiengesellschaft | Piperazine derivatives and their use as anti-inflammatory agents |
AU2740900A (en) * | 1999-01-29 | 2000-08-18 | Millennium Pharmaceuticals, Inc. | Method of treating demyelinating inflammatory disease using ccr1 antagonists |
NZ521290A (en) * | 2000-03-31 | 2004-10-29 | Pfizer Prod Inc | Novel piperazine derivatives |
US6740636B2 (en) * | 2000-07-31 | 2004-05-25 | Schering Aktiengesellschaft | Non-peptide CCR1 receptor antagonists in combination with cyclosporin A for the treatment of heart transplant rejection |
LT5132B (lt) | 2000-07-31 | 2004-05-25 | Schering Aktiengesellschaft | Nepeptidiniai ccr1 receptorių antagonistai derinyje su ciklosporinu a širdies transplanto atmetimui gydyti |
WO2002030358A2 (en) * | 2000-10-11 | 2002-04-18 | Tularik Inc. | Modulation of ccr4 function |
CA2423789A1 (en) * | 2000-10-19 | 2002-04-25 | Pfizer Products Inc. | Bridged piperazine derivatives |
UY27003A1 (es) * | 2000-11-06 | 2002-07-31 | Schering Ag | Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer |
WO2002094264A1 (en) * | 2001-05-23 | 2002-11-28 | Tularik Inc. | Ccr4 antagonists |
US6861424B2 (en) | 2001-06-06 | 2005-03-01 | Schering Aktiengesellschaft | Platelet adenosine diphosphate receptor antagonists |
CZ20033455A3 (en) | 2001-06-20 | 2004-06-16 | Pfizer Products Inc. | Novel sulfonic acid derivatives |
ES2257555T3 (es) * | 2001-06-20 | 2006-08-01 | MERCK & CO., INC. | Inhibidores de dipeptidilpeptidasa para el tratamiento de la diabetes. |
US6812230B2 (en) * | 2001-08-07 | 2004-11-02 | Schering Aktiengesellschaft | Non-peptide CCR1 receptor antagonists for the treatment of progressive renal fibrosis |
US7354923B2 (en) * | 2001-08-10 | 2008-04-08 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
US7732451B2 (en) * | 2001-08-10 | 2010-06-08 | Palatin Technologies, Inc. | Naphthalene-containing melanocortin receptor-specific small molecule |
WO2003013571A1 (en) * | 2001-08-10 | 2003-02-20 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
US7718802B2 (en) | 2001-08-10 | 2010-05-18 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
US7456184B2 (en) * | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
US7655658B2 (en) * | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
US20030087913A1 (en) * | 2001-10-18 | 2003-05-08 | Schering Ag | Solid pharmaceutical agent formulation for a piperazine urea derivative |
DE10152351B4 (de) * | 2001-10-18 | 2005-09-22 | Schering Ag | Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat |
MXPA04002423A (es) * | 2001-10-22 | 2004-05-31 | Pfizer Prod Inc | Derivados de piperazina con actividad antagonista del receptor ccr1. |
KR100472086B1 (ko) * | 2001-11-23 | 2005-02-21 | 한국화학연구원 | 항산화 활성을 갖는 3,5-디알콕시-4-히드록시페닐기로치환된 피페라진 유도체, 그의 제조방법 및 이를 포함하는약학적 조성물 |
GB0203299D0 (en) * | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel compounds |
GB0207447D0 (en) * | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
TW200400035A (en) | 2002-03-28 | 2004-01-01 | Glaxo Group Ltd | Novel compounds |
US20050256130A1 (en) * | 2002-06-12 | 2005-11-17 | Chemocentryx, Inc. | Substituted piperazines |
US7842693B2 (en) * | 2002-06-12 | 2010-11-30 | Chemocentryx, Inc. | Substituted piperazines |
ES2329356T3 (es) | 2002-06-12 | 2009-11-25 | Chemocentryx, Inc. | Derivados de piperazina 1-arilo-4-sustituidos utilizados como antagonistas de ccr1 para el tratamiento de enfermedades inflamatorias e inmunitarias. |
US7589199B2 (en) | 2002-06-12 | 2009-09-15 | Chemocentryx, Inc. | Substituted piperazines |
US6727241B2 (en) * | 2002-06-12 | 2004-04-27 | Chemocentryx | Anti-inflammatory compositions and methods of use |
US20040092529A1 (en) * | 2002-10-30 | 2004-05-13 | Pfizer Inc | Methods of using piperazine derivatives |
BR0317222A (pt) | 2002-12-11 | 2005-11-01 | Schering Aktiengellschaft | Compostos de 2-aminocarbonil-quinolina como antagonistas dos receptores de difosfato de adenisina de plaquetas |
MXPA05006229A (es) * | 2002-12-13 | 2005-08-19 | Pfizer Prod Inc | Derivados de piperazina que contienen fosforo como antagonistas de ccr1. |
US7727991B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific single acyl piperazine compounds |
US7968548B2 (en) | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
US7727990B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine and keto-piperazine compounds |
WO2005102340A1 (en) * | 2003-05-30 | 2005-11-03 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
BRPI0413846A (pt) * | 2003-08-22 | 2006-10-24 | Schering Aktiengellschaft | derivados de piperazina inibidores de quimiocina e seu uso para tratar miocardite |
AR045536A1 (es) | 2003-08-29 | 2005-11-02 | Ranbaxy Lab Ltd | Inhibidores de la fosfodiesterasa tipo -iv |
US9198887B2 (en) | 2003-09-15 | 2015-12-01 | Nanopharmaceuticals Llc | Thyroid hormone analogs and methods of use |
US8668926B1 (en) | 2003-09-15 | 2014-03-11 | Shaker A. Mousa | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof |
CN1878545A (zh) | 2003-09-15 | 2006-12-13 | 奥德威研究院 | 甲状腺激素类似物及其使用方法 |
US8071134B2 (en) | 2003-09-15 | 2011-12-06 | Ordway Research Institute, Inc. | Thyroid hormone analogs and methods of use |
US20050192282A1 (en) * | 2004-02-06 | 2005-09-01 | Schering Aktiengesellschaft | Chemokine inhibiting piperazine derivatives and their use to treat multiple myeloma |
US20080119471A1 (en) * | 2004-02-24 | 2008-05-22 | Ulrike Kaufmann | Piperazine urea derivatives for the treatment of endometriosis |
SE0400440D0 (sv) * | 2004-02-25 | 2004-02-25 | Active Biotech Ab | Novel Cinnamic Amides |
SE0400441D0 (sv) | 2004-02-25 | 2004-02-25 | Active Biotech Ab | Novel Benzofurans and Indols |
AU2005219438B2 (en) * | 2004-03-03 | 2011-02-17 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
US7435831B2 (en) * | 2004-03-03 | 2008-10-14 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
US7709484B1 (en) | 2004-04-19 | 2010-05-04 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
ES2251292B1 (es) * | 2004-04-20 | 2007-07-01 | Inke, S.A. | Procedimiento para la obtencion de un compuesto farmaceuticamente activo y de sus intermedios de sintesis. |
GB0409236D0 (en) * | 2004-04-26 | 2004-05-26 | Novartis Ag | Organic compounds |
JP2008513461A (ja) | 2004-09-15 | 2008-05-01 | オードウェイ リサーチ インスティテュート | 血管形成を促進する甲状腺ホルモンアナログ |
EP1749519A1 (de) | 2005-08-05 | 2007-02-07 | Schering Aktiengesellschaft | Arzneiform mit Retardtierter pH-unabhängiger Wirkstofffreisetzung für Wirkstoffe mit starker pH-abhängiger Löslichkeit |
US20070087056A1 (en) * | 2005-08-09 | 2007-04-19 | Claudia Guthmann | Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility |
US9498536B2 (en) | 2005-09-15 | 2016-11-22 | Nanopharmaceuticals Llc | Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders |
US10130686B2 (en) | 2005-09-15 | 2018-11-20 | Nanopharmaceuticals Llc | Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders |
WO2007035612A2 (en) | 2005-09-16 | 2007-03-29 | Ordway Research Institute, Inc. | Polyphenol conjugates as rgd-binding compounds and methods of use |
CN101321525B (zh) * | 2005-12-01 | 2013-01-30 | 霍夫曼-拉罗奇有限公司 | 作为l-cpt1抑制剂的杂芳基取代的哌啶衍生物 |
JP5682051B2 (ja) * | 2006-05-18 | 2015-03-11 | ファーマサイクリックス,インク. | 細胞内キナーゼ阻害剤 |
FR2902426B1 (fr) * | 2006-06-19 | 2008-09-05 | Pierre Fabre Medicament Sa | Derives de cinnamoyl-piperazine |
US7834017B2 (en) | 2006-08-11 | 2010-11-16 | Palatin Technologies, Inc. | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents |
AP2780A (en) | 2006-10-18 | 2013-09-30 | Pfizer Prod Inc | Biaryl ether urea compounds |
CA2673133C (en) | 2006-12-22 | 2016-08-30 | Clf Medical Technology Acceleration Program, Inc. | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof |
WO2008090357A2 (en) * | 2007-01-24 | 2008-07-31 | Palatin Technologies, Inc. | N, n; -substituted piperazines binding to melanocortin receptor |
EP1958947A1 (en) | 2007-02-15 | 2008-08-20 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type 4 |
WO2010120506A1 (en) | 2009-03-31 | 2010-10-21 | Ordway Research Institute, Inc. | Combination treatment of cancer with cetuximab and tetrac |
CA2765792C (en) | 2009-06-17 | 2017-03-28 | Ordway Research Institute, Inc. | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof |
US9492439B2 (en) | 2010-03-11 | 2016-11-15 | New York University | Amido compounds as RORγt modulators and uses thereof |
US8802240B2 (en) | 2011-01-06 | 2014-08-12 | Nanopharmaceuticals Llc | Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells |
KR101380466B1 (ko) * | 2011-09-27 | 2014-04-02 | 한국생명공학연구원 | HIF―1α 활성을 저해하는 신규 화합물 및 그 제조방법 |
CN102408395B (zh) * | 2011-10-24 | 2014-04-02 | 广西师范大学 | 新的哌嗪和高哌嗪类衍生物及其制备方法和应用 |
US20140329809A1 (en) | 2011-10-28 | 2014-11-06 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
US20140221335A1 (en) | 2013-02-06 | 2014-08-07 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
US9115093B2 (en) | 2013-03-04 | 2015-08-25 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
BR112016000779A8 (pt) | 2013-07-18 | 2020-01-07 | Novartis Ag | inibidores de autotaxina que compreendem núcleo do ciclo de benzilamida de anel heteroaromático, seus usos, composição e combinação farmacêuticas |
CN103724296B (zh) * | 2013-12-12 | 2015-09-02 | 南京医科大学 | 芳基取代的哌嗪羰基衍生物及其制备方法和应用 |
WO2015186591A1 (ja) * | 2014-06-06 | 2015-12-10 | 国立研究開発法人理化学研究所 | カルス誘導剤及びカルス誘導方法 |
CN105218501A (zh) * | 2014-07-03 | 2016-01-06 | 南京大学 | 含哌嗪环的香豆素类衍生物及其制备与在抗菌药物中的应用 |
US9475779B2 (en) | 2014-07-31 | 2016-10-25 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
US9657015B2 (en) | 2014-07-31 | 2017-05-23 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
WO2016056581A1 (ja) | 2014-10-08 | 2016-04-14 | 国立研究開発法人理化学研究所 | 植物成長促進剤及び植物成長促進方法 |
CN107709314A (zh) | 2015-06-11 | 2018-02-16 | 巴斯利尔药物国际股份公司 | 外排泵抑制剂及其治疗性用途 |
AU2017279536A1 (en) | 2016-06-07 | 2018-12-20 | Nanopharmaceuticals, Llc | Non-cleavable polymer conjugated with αvβ3 integrin thyroid antagonists |
US11548893B2 (en) | 2017-07-15 | 2023-01-10 | Arisan Therapeutics Inc. | Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection |
US11351137B2 (en) | 2018-04-11 | 2022-06-07 | Nanopharmaceuticals Llc | Composition and method for dual targeting in treatment of neuroendocrine tumors |
US10328043B1 (en) | 2018-04-11 | 2019-06-25 | Nanopharmaceuticals, Llc. | Composition and method for dual targeting in treatment of neuroendocrine tumors |
CN110372638B (zh) * | 2018-04-13 | 2023-09-22 | 中国药科大学 | 哌嗪类ampk激动剂及其医药用途 |
CN108484558A (zh) * | 2018-05-14 | 2018-09-04 | 中国药科大学 | 黄酮类ampk激动剂及其医药用途 |
US10961204B1 (en) | 2020-04-29 | 2021-03-30 | Nanopharmaceuticals Llc | Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors |
AU2022287943A1 (en) * | 2021-06-07 | 2023-12-07 | Nanopharmaceuticals Llc | Composition and method for dual targeting in treatment of neuroendocrine tumors |
EP4115885A1 (en) | 2021-07-05 | 2023-01-11 | Charité - Universitätsmedizin Berlin | A pharmaceutical composition comprising bay 86-5277 and salts thereof for use in the treatment of viral infections and hyperinflammation |
US11723888B2 (en) | 2021-12-09 | 2023-08-15 | Nanopharmaceuticals Llc | Polymer conjugated thyrointegrin antagonists |
WO2023235297A1 (en) * | 2022-06-03 | 2023-12-07 | Imbria Pharmaceuticals, Inc. | Compounds and methods for increasing efficiency of cardiac metabolism |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3324117A (en) | 1967-06-06 | Carboxylic acid piperazides and process for their manufacture | ||
FR7524M (US20030139425A1-20030724-C00001.png) | 1968-03-12 | 1969-12-15 | ||
DE2304155A1 (de) * | 1973-01-29 | 1974-08-01 | Ichthyol Ges Cordes Hermanni & | N-acylierte substituierte piperazinbzw. homopiperazinderivate, sowie verfahren zu ihrer herstellung |
DE2730174C2 (de) | 1977-07-04 | 1981-12-10 | Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren | Aminobenzoesäurederivate und Arzneimittel enthaltend solche Aminobenzoesäurederivate |
EP0018497B1 (de) * | 1979-04-06 | 1982-04-28 | Bayer Ag | Azolyloxy-essigsäureamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide |
IT1151533B (it) | 1982-03-29 | 1986-12-24 | Ravizza Spa | Procedimento per la preparazione di p. clorofenossiacetil-piperonilpiperazina |
IT1151532B (it) | 1982-03-29 | 1986-12-24 | Ravizza Spa | Procedimento per la preparazione di p. clorofenossiacetil-piperonilpiperazina |
US4439606A (en) * | 1982-05-06 | 1984-03-27 | American Cyanamid Company | Antiatherosclerotic 1-piperazinecarbonyl compounds |
EP0190685B1 (en) | 1985-02-04 | 1992-07-01 | G.D. Searle & Co. | Heterocyclic amides |
DE3614363A1 (de) * | 1986-04-28 | 1987-10-29 | Hoechst Ag | Benzothiazinon-derivate, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und deren verwendung |
JPS6314774A (ja) | 1986-07-07 | 1988-01-21 | Mitsubishi Chem Ind Ltd | ピリダジノン誘導体又はその塩類 |
CN1030415A (zh) | 1987-02-20 | 1989-01-18 | 山之内制药株式会社 | 饱和的杂环碳酰胺衍生物和它的制备方法 |
FR2611713B1 (fr) | 1987-02-27 | 1990-11-30 | Adir | Nouveaux derives de l'acide (dihydro-2,3 oxo-2 benzofurannyl-3)-2 acetique, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
EP0284632A1 (en) | 1987-03-30 | 1988-10-05 | Shosuke Okamoto | Phenylalanine derivative and proteinase inhibitor |
CS260089B1 (cs) | 1987-05-12 | 1988-11-15 | Miroslav Protiva | Piperazidy methoxyfenoxyoctových kyselin a jejich hydrochloridy |
AT389112B (de) | 1987-10-08 | 1989-10-25 | Hoechst Ag | Benzothiazinon-derivate, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und deren verwendung |
FR2623808B1 (fr) | 1987-12-01 | 1990-03-09 | Adir | Nouveaux derives flavonoides (benzyl-4 piperazinyl-1)-2 oxo-2 ethylene substitues, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
NZ228329A (en) | 1988-03-18 | 1991-12-23 | Mitsui Toatsu Chemicals | Catechol derivatives and pharmaceutical compositions thereof |
US5232923A (en) * | 1988-03-18 | 1993-08-03 | Mitsui Toatsu Chemicals, Incorporated | Catechol derivatives and pharmaceutical preparations containing same |
US5010080A (en) | 1988-12-02 | 1991-04-23 | G. D. Searle & Co. | Use of heterocyclic amides to inhibit tumor metastasis |
US5089506A (en) * | 1990-04-30 | 1992-02-18 | G. D. Searle & Co. | Ethanobicyclic amine derivatives for cns disorders |
US5190922A (en) | 1991-06-04 | 1993-03-02 | Abbott Laboratories | Terminally modified tri-, tetra- and pentapeptide anaphylatoxin receptor ligands |
FR2689127B1 (fr) * | 1992-03-31 | 1994-05-06 | Adir Cie | Nouvelles 3', 5' -ditertbutyl-4'-hydroxy flavones, leur procede de preparation et les compositions pharmaceutiques les renfermant. |
US5272175A (en) | 1992-05-20 | 1993-12-21 | G. D. Searle & Co. | Substituted tyrosyl diamide compounds |
US5389645A (en) | 1992-08-13 | 1995-02-14 | G. D. Searle & Co. | Substituted tyrosyl diamine amide compounds |
DE59309867D1 (de) | 1992-09-03 | 1999-12-16 | Boehringer Ingelheim Pharma | Neue aminosäurederivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen |
IL110040A (en) | 1993-06-29 | 2000-07-16 | Nissan Chemical Ind Ltd | Pyridazinone derivatives their preparation and pharmaceutical compositions comprising them |
CN1114834A (zh) | 1993-09-28 | 1996-01-10 | 大塚制药株式会社 | 抗糖尿病剂 |
IL111730A (en) | 1993-11-29 | 1998-12-06 | Fujisawa Pharmaceutical Co | Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them |
FR2724656B1 (fr) | 1994-09-15 | 1996-12-13 | Adir | Nouveaux derives du benzopyranne, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
ES2197238T3 (es) | 1995-05-02 | 2004-01-01 | Schering Corporation | Derivados de piperazina como antagonistas de neuroquininas. |
US6281212B1 (en) | 1996-07-12 | 2001-08-28 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
US6140338A (en) | 1996-07-29 | 2000-10-31 | Banyu Pharmaceutical, Co., Ltd. | Chemokine receptor antagonists |
DK0966443T3 (da) | 1997-02-26 | 2009-03-09 | Pfizer | Heteroaryl-hexansyre amidderivater, deres fremstilling og deres anvendelse som selektive inhibitorer af MIP-1-alfa binding til dens CCR1 receptor |
US6207665B1 (en) * | 1997-06-12 | 2001-03-27 | Schering Aktiengesellschaft | Piperazine derivatives and their use as anti-inflammatory agents |
KR20010111298A (ko) | 2000-02-05 | 2001-12-17 | 버텍스 파마슈티칼스 인코포레이티드 | Erk의 억제제로서 유용한 피라졸 조성물 |
US6521619B2 (en) | 2000-06-29 | 2003-02-18 | Icos Corporation | Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents |
US6518276B2 (en) | 2000-08-31 | 2003-02-11 | Syntex (U.S.A.) Llc | 7-oxo-pyridopyrimidines (II) |
-
1998
- 1998-06-09 US US09/094,397 patent/US6207665B1/en not_active Expired - Fee Related
- 1998-06-11 EE EEP200200682A patent/EE200200682A/xx unknown
- 1998-06-11 IL IL13239898A patent/IL132398A/en not_active IP Right Cessation
- 1998-06-11 SK SK79-2005A patent/SK285445B6/sk unknown
- 1998-06-11 CA CA002293382A patent/CA2293382C/en not_active Expired - Fee Related
- 1998-06-11 SK SK1713-99A patent/SK285162B6/sk unknown
- 1998-06-11 EP EP02090193A patent/EP1254899B1/en not_active Expired - Lifetime
- 1998-06-11 ES ES98937467T patent/ES2191320T3/es not_active Expired - Lifetime
- 1998-06-11 DE DE69811363T patent/DE69811363T2/de not_active Expired - Fee Related
- 1998-06-11 PT PT02090193T patent/PT1254899E/pt unknown
- 1998-06-11 EA EA200200262A patent/EA200200262A1/ru unknown
- 1998-06-11 CZ CZ19994481A patent/CZ295784B6/cs not_active IP Right Cessation
- 1998-06-11 AT AT02090193T patent/ATE296292T1/de not_active IP Right Cessation
- 1998-06-11 EE EEP200200683A patent/EE200200683A/xx unknown
- 1998-06-11 DK DK98937467T patent/DK0988292T3/da active
- 1998-06-11 KR KR1019997011718A patent/KR100549137B1/ko not_active IP Right Cessation
- 1998-06-11 EP EP98937467A patent/EP0988292B1/en not_active Expired - Lifetime
- 1998-06-11 JP JP50161199A patent/JP2002503239A/ja not_active Ceased
- 1998-06-11 WO PCT/EP1998/003503 patent/WO1998056771A2/en active IP Right Grant
- 1998-06-11 EE EEP200200684A patent/EE200200684A/xx unknown
- 1998-06-11 EE EEP199900565A patent/EE04056B1/xx not_active IP Right Cessation
- 1998-06-11 HU HU0003929A patent/HUP0003929A3/hu unknown
- 1998-06-11 EA EA199901063A patent/EA004038B1/ru not_active IP Right Cessation
- 1998-06-11 PL PL98337758A patent/PL337758A1/xx not_active Application Discontinuation
- 1998-06-11 AT AT98937467T patent/ATE232522T1/de not_active IP Right Cessation
- 1998-06-11 ES ES02090193T patent/ES2242824T3/es not_active Expired - Lifetime
- 1998-06-11 TR TR1999/03034T patent/TR199903034T2/xx unknown
- 1998-06-11 DK DK02090193T patent/DK1254899T3/da active
- 1998-06-11 AU AU86258/98A patent/AU735462B2/en not_active Ceased
- 1998-06-11 DE DE69830341T patent/DE69830341T2/de not_active Expired - Fee Related
-
1999
- 1999-11-19 IS IS5258A patent/IS2241B/is unknown
- 1999-12-09 NO NO19996068A patent/NO317343B1/no unknown
-
2000
- 2000-11-14 US US09/713,606 patent/US6541476B1/en not_active Expired - Fee Related
- 2000-11-15 US US09/713,881 patent/US6534509B1/en not_active Expired - Fee Related
- 2000-11-16 US US09/714,937 patent/US6573266B1/en not_active Expired - Fee Related
- 2000-11-29 US US09/726,808 patent/US6555537B2/en not_active Expired - Fee Related
-
2003
- 2003-01-17 US US10/347,529 patent/US6972290B2/en not_active Expired - Fee Related
- 2003-01-17 US US10/347,530 patent/US6977258B2/en not_active Expired - Fee Related
- 2003-03-26 NO NO20031373A patent/NO20031373D0/no not_active Application Discontinuation
-
2005
- 2005-10-13 US US11/248,618 patent/US7268140B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2191320T3 (es) | Derivados de piperazina y su uso como agentes anti-inflamatorios. | |
PA8462401A1 (es) | Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos | |
CO4930259A1 (es) | Derivados 6,6-heterobiciclicos sustituidos y composiciones farmaceuticas que los contienen | |
SV1999000016A (es) | Derivados de 2-(purin-9-il-tetrahidrofuran-3,4-diol ref. pg3443/sv | |
ECSP941104A (es) | Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
SV1999000009A (es) | Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol ref. pg3388/sv | |
HN1998000157A (es) | Agonistas de prostaglandinas | |
GT200500007A (es) | [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia. | |
ES2058185T3 (es) | Derivados de camptotecina y procedimiento para su preparacion. | |
ECSP034797A (es) | DERIVADOS DIHIDRO-BENZO[b][1,4]DIAZEPIN-2-ONA COMO ANTAGONISTAS II MGLUR2 | |
GT199700015A (es) | Inhibidores de metaloproteinasa, composiciones farmaceuticas que las contienen y su uso farmaceutico y metodosyeficazproducto intermedio para su preparacion. | |
AR019503A1 (es) | Utilizacion de derivados sustituidos en 3 del estilbeno como agentes activos desodorantes en las composiciones cosmeticas | |
HN2002000365A (es) | Lactamas como antagonistas de taquiquininas | |
SE9801494D0 (sv) | Novel use | |
ES2157442T3 (es) | Derivados de benzoisoxazol y de indazol, utilizados como agentes neurolepticos. | |
ES2172611T3 (es) | Suspension acuosa estable de mesalazina para uso topico. | |
PA8444901A1 (es) | Derivados de 5-aroilnaftaleno como agentes anti-inflamatorios | |
AR026756A1 (es) | Nuevas combinaciones terapeuticas (s)-2-bencilamino-metil)-2,3,8,9-tetrahidro-7h-1,4-dioxino[2,3-e]indol-8-ona y neuroleticos para el tratamiento oprevencion de desordenes psicoticos | |
ECSP003751A (es) | Nuevos compuestos | |
ES2188797T3 (es) | Sales de n-(4-oxo-2-(1h-tetrazoil-5-il)-4h-1 benzopran-8-il)-4-(4-fenilbutoxi)benzamida. | |
GT199900007A (es) | Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol. | |
ECSP951367A (es) | Derivados tetraciclicos procesos para su preparacion y su uso | |
ECSP972293A (es) | Derivados de naftiridina | |
MX9301870A (es) | Antagonistas receptores de angiotensina ii | |
UY25023A1 (es) | 1,3-oxatiolanos sustituidos y 1,3-ditiolanos sustituidos con propiedades antivirales |